• Skip to content (access key 1)
  • Skip to search (access key 7)
FWF — Austrian Science Fund
  • Go to overview page Discover

    • Research Radar
    • Discoveries
      • Emmanuelle Charpentier
      • Adrian Constantin
      • Monika Henzinger
      • Ferenc Krausz
      • Wolfgang Lutz
      • Walter Pohl
      • Christa Schleper
      • Anton Zeilinger
    • scilog Magazine
    • Awards
      • FWF Wittgenstein Awards
      • FWF START Awards
    • excellent=austria
      • Clusters of Excellence
      • Emerging Fields
    • In the Spotlight
      • 40 Years of Erwin Schrödinger Fellowships
      • Quantum Austria
    • Dialogs and Talks
      • think.beyond Summit
    • E-Book Library
  • Go to overview page Funding

    • Portfolio
      • excellent=austria
        • Clusters of Excellence
        • Emerging Fields
      • Projects
        • Principal Investigator Projects
        • Principal Investigator Projects International
        • Clinical Research
        • 1000 Ideas
        • Arts-Based Research
        • FWF Wittgenstein Award
      • Careers
        • ESPRIT
        • FWF ASTRA Awards
        • Erwin Schrödinger
        • Elise Richter
        • Elise Richter PEEK
        • doc.funds
        • doc.funds.connect
      • Collaborations
        • Specialized Research Groups
        • Special Research Areas
        • Research Groups
        • International – Multilateral Initiatives
        • #ConnectingMinds
      • Communication
        • Top Citizen Science
        • Science Communication
        • Book Publications
        • Digital Publications
        • Open-Access Block Grant
      • Subject-Specific Funding
        • AI Mission Austria
        • Belmont Forum
        • ERA-NET HERA
        • ERA-NET NORFACE
        • ERA-NET QuantERA
        • ERA-NET TRANSCAN
        • Alternative Methods to Animal Testing
        • European Partnership Biodiversa+
        • European Partnership ERA4Health
        • European Partnership ERDERA
        • European Partnership EUPAHW
        • European Partnership FutureFoodS
        • European Partnership OHAMR
        • European Partnership PerMed
        • European Partnership Water4All
        • Gottfried and Vera Weiss Award
        • netidee SCIENCE
        • Herzfelder Foundation Projects
        • Quantum Austria
        • Rückenwind Funding Bonus
        • Zero Emissions Award
      • International Collaborations
        • Belgium/Flanders
        • Germany
        • France
        • Italy/South Tyrol
        • Japan
        • Luxembourg
        • Poland
        • Switzerland
        • Slovenia
        • Taiwan
        • Tyrol–South Tyrol–Trentino
        • Czech Republic
        • Hungary
    • Step by Step
      • Find Funding
      • Submitting Your Application
      • International Peer Review
      • Funding Decisions
      • Carrying out Your Project
      • Closing Your Project
      • Further Information
        • Integrity and Ethics
        • Inclusion
        • Applying from Abroad
        • Personnel Costs
        • PROFI
        • Final Project Reports
        • Final Project Report Survey
    • FAQ
      • Project Phase PROFI
        • Accounting for Approved Funds
        • Labor and Social Law
        • Project Management
      • Project Phase Ad Personam
        • Accounting for Approved Funds
        • Labor and Social Law
        • Project Management
      • Expiring Programs
        • FWF START Awards
  • Go to overview page About Us

    • Mission Statement
    • FWF Video
    • Values
    • Facts and Figures
    • Annual Report
    • What We Do
      • Research Funding
        • Matching Funds Initiative
      • International Collaborations
      • Studies and Publications
      • Equal Opportunities and Diversity
        • Objectives and Principles
        • Measures
        • Creating Awareness of Bias in the Review Process
        • Terms and Definitions
        • Your Career in Cutting-Edge Research
      • Open Science
        • Open Access Policy
          • Open Access Policy for Peer-Reviewed Publications
          • Open Access Policy for Peer-Reviewed Book Publications
          • Open Access Policy for Research Data
        • Research Data Management
        • Citizen Science
        • Open Science Infrastructures
        • Open Science Funding
      • Evaluations and Quality Assurance
      • Academic Integrity
      • Science Communication
      • Philanthropy
      • Sustainability
    • History
    • Legal Basis
    • Organization
      • Executive Bodies
        • Executive Board
        • Supervisory Board
        • Assembly of Delegates
        • Scientific Board
        • Juries
      • FWF Office
    • Jobs at FWF
  • Go to overview page News

    • News
    • Press
      • Logos
    • Calendar
      • Post an Event
      • FWF Informational Events
    • Job Openings
      • Enter Job Opening
    • Newsletter
  • Discovering
    what
    matters.

    FWF-Newsletter Press-Newsletter Calendar-Newsletter Job-Newsletter scilog-Newsletter

    SOCIAL MEDIA

    • LinkedIn, external URL, opens in a new window
    • Twitter, external URL, opens in a new window
    • Facebook, external URL, opens in a new window
    • Instagram, external URL, opens in a new window
    • YouTube, external URL, opens in a new window

    SCILOG

    • Scilog — The science magazine of the Austrian Science Fund (FWF)
  • elane login, external URL, opens in a new window
  • Scilog external URL, opens in a new window
  • de Wechsle zu Deutsch

  

Replace mice xenografts by MIcrofluidic CancerogEnesis Chips

Replace mice xenografts by MIcrofluidic CancerogEnesis Chips

Heinz Wanzenböck (ORCID: 0000-0002-0893-273X)
  • Grant DOI 10.55776/P37331
  • Funding program Principal Investigator Projects
  • Status ongoing
  • Start October 1, 2024
  • End September 30, 2027
  • Funding amount € 399,998
  • Project website
  • E-mail

Disciplines

Electrical Engineering, Electronics, Information Engineering (10%); Medical-Theoretical Sciences, Pharmacy (45%); Medical Engineering (45%)

Keywords

    Tumorigenicity, Microfluidic Chip, Epidermis-Dermis-Equivalent, Immunocompetent, Bioimpedance, Melanoma

Abstract

In the EU, cancer is the second leading cause of death. It`s a shocking fact that 31% of men and 25% of women are expected to face a cancer diagnosis before the age of 75. But here`s the exciting part personalized medicine is changing the game! This innovative approach promises earlier detection and super-targeted treatments tailored to each patient. For years, scientists have relied on mouse xenograft models for cancer research. They inject human tumor cells into immunosuppressed mice and watch how the cancer grows. Mouse xenografts are the state-of-the-art model for assessing tumor aggressiveness and testing new cancer drugs. But with personalized medicine on the rise, the demand for these mouse models is skyrocketing at a whopping 16.4% annual increase! In fact, the number of mouse experiments is set to double in the next five years. This groundbreaking project offers an animal-friendly alternative: replacing mouse xenograft models with a cutting-edge human model on a microchip! This not only spares the lives of countless healthy mice but also offers a more accurate representation of human cancer. Why? Because what`s effective in a mouse doesn`t always work in humans. Many promising drugs fail in clinical trials because of this species gap, leaving patients without effective treatments. Our microchip model uses human cancer cells in a meticulously controlled microenvironment. By integrating microelectrodes for non-destructive, continuous monitoring, we can track tumor growth and the effects of anti-cancer drugs in real-time. Imagine a chip that mimics human skin, complete with vascular structures and immune cells its like having a tiny, realistic model of human cancer right in the lab! We are initiating our research with human melanoma cell lines introduced into a human epidermis/dermis-equivalent chip. Our goal is to prove that these human cancer-on-a-chip models can completely replace mouse models. In the final stages, we`ll even test patient-derived tumor cells on the chip, paving the way for truly personalized therapies. This project could revolutionize personalized cancer treatment and offer profound insights into tumor development and therapy in humans. Get ready for a future where cancer research is faster, more accurate, and more humane! The future of cancer treatment is here, and it`s happening on a microchip!

Research institution(s)
  • Medizinische Universität Graz - 35%
  • Technische Universität Wien - 65%
Project participants
  • Beate Rinner, Medizinische Universität Graz , associated research partner
  • Martin Frauenlob, Technische Universität Wien , national collaboration partner
  • Peter Ertl, Technische Universität Wien , national collaboration partner
  • Sonia Prado López, Technische Universität Wien , national collaboration partner
  • Doris Wilflingseder, Veterinärmedizinische Universität Wien , national collaboration partner

Discovering
what
matters.

Newsletter

FWF-Newsletter Press-Newsletter Calendar-Newsletter Job-Newsletter scilog-Newsletter

Contact

Austrian Science Fund (FWF)
Georg-Coch-Platz 2
(Entrance Wiesingerstraße 4)
1010 Vienna

office(at)fwf.ac.at
+43 1 505 67 40

General information

  • Job Openings
  • Jobs at FWF
  • Press
  • Philanthropy
  • scilog
  • FWF Office
  • Social Media Directory
  • LinkedIn, external URL, opens in a new window
  • Twitter, external URL, opens in a new window
  • Facebook, external URL, opens in a new window
  • Instagram, external URL, opens in a new window
  • YouTube, external URL, opens in a new window
  • Cookies
  • Whistleblowing/Complaints Management
  • Accessibility Statement
  • Data Protection
  • Acknowledgements
  • Social Media Directory
  • © Österreichischer Wissenschaftsfonds FWF
© Österreichischer Wissenschaftsfonds FWF